Cardio Diagnostics (CDIO) Competitors

$1.55 -0.13 (-7.74%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$1.54 -0.01 (-0.32%)

As of 05/15/2026 06:07 PM Eastern

CDIO vs. AKAN, VYNE, KZIA, KTTA, and CPHI

Should you buy Cardio Diagnostics stock or one of its competitors? MarketBeat compares Cardio Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardio Diagnostics include Akanda (AKAN), VYNE Therapeutics (VYNE), Novogen (KZIA), Pasithea Therapeutics (KTTA), and China Pharma (CPHI). These companies are all part of the "pharmaceutical products" industry.

How does Cardio Diagnostics compare to Akanda?

Cardio Diagnostics (NASDAQ:CDIO) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Akanda has higher revenue and earnings than Cardio Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$14.83K	309.48	-$6.50M	-$3.72	N/A
Akanda	$836.66K	13.07	-$4.10M	N/A	N/A

In the previous week, Akanda had 3 more articles in the media than Cardio Diagnostics. MarketBeat recorded 5 mentions for Akanda and 2 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.87 beat Akanda's score of 0.89 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Very Positive
Akanda	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Akanda has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,612.50%. Akanda's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%
Akanda	N/A	N/A	N/A

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cardio Diagnostics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, Akanda has a beta of 14.49, suggesting that its stock price is 1,349% more volatile than the broader market.

Summary

Akanda beats Cardio Diagnostics on 8 of the 11 factors compared between the two stocks.

How does Cardio Diagnostics compare to VYNE Therapeutics?

Cardio Diagnostics (NASDAQ:CDIO) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

VYNE Therapeutics has a net margin of -4,646.14% compared to Cardio Diagnostics' net margin of -40,612.50%. Cardio Diagnostics' return on equity of -71.75% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%
VYNE Therapeutics	-4,646.14%	-74.86%	-63.87%

Cardio Diagnostics has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$14.83K	309.48	-$6.50M	-$3.72	N/A
VYNE Therapeutics	$570K	39.17	-$26.48M	-$0.78	N/A

In the previous week, VYNE Therapeutics had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for VYNE Therapeutics and 2 mentions for Cardio Diagnostics. VYNE Therapeutics' average media sentiment score of 1.89 beat Cardio Diagnostics' score of 1.87 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardio Diagnostics	Very Positive
VYNE Therapeutics	Very Positive

Cardio Diagnostics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market.

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

VYNE Therapeutics beats Cardio Diagnostics on 8 of the 14 factors compared between the two stocks.

How does Cardio Diagnostics compare to Novogen?

Novogen (NASDAQ:KZIA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Novogen currently has a consensus target price of $21.00, suggesting a potential upside of 59.57%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Novogen is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Novogen has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,612.50%. Novogen's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%

Cardio Diagnostics has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	723.80	-$13.41M	N/A	N/A
Cardio Diagnostics	$14.83K	309.48	-$6.50M	-$3.72	N/A

In the previous week, Novogen and Novogen both had 2 articles in the media. Cardio Diagnostics' average media sentiment score of 1.87 beat Novogen's score of 0.44 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Neutral
Cardio Diagnostics	Very Positive

Novogen has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Novogen beats Cardio Diagnostics on 9 of the 13 factors compared between the two stocks.

How does Cardio Diagnostics compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Pasithea Therapeutics and Pasithea Therapeutics both had 2 articles in the media. Pasithea Therapeutics' average media sentiment score of 1.87 equaled Cardio Diagnostics'average media sentiment score.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
Cardio Diagnostics	Very Positive

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pasithea Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -40,612.50%. Cardio Diagnostics' return on equity of -71.75% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-85.48%	-77.42%
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 284.57%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Pasithea Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cardio Diagnostics has higher revenue and earnings than Pasithea Therapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A
Cardio Diagnostics	$14.83K	309.48	-$6.50M	-$3.72	N/A

Pasithea Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market.

Summary

Pasithea Therapeutics beats Cardio Diagnostics on 7 of the 13 factors compared between the two stocks.

How does Cardio Diagnostics compare to China Pharma?

Cardio Diagnostics (NASDAQ:CDIO) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

China Pharma has higher revenue and earnings than Cardio Diagnostics. China Pharma is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$14.83K	309.48	-$6.50M	-$3.72	N/A
China Pharma	$4.14M	10.17	-$3.08M	-$0.75	N/A

China Pharma has a net margin of -85.56% compared to Cardio Diagnostics' net margin of -40,612.50%. China Pharma's return on equity of -63.93% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-40,612.50%	-71.75%	-66.25%
China Pharma	-85.56%	-63.93%	-31.42%

In the previous week, Cardio Diagnostics had 1 more articles in the media than China Pharma. MarketBeat recorded 2 mentions for Cardio Diagnostics and 1 mentions for China Pharma. Cardio Diagnostics' average media sentiment score of 1.87 beat China Pharma's score of -0.59 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Very Positive
China Pharma	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cardio Diagnostics has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, China Pharma has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

8.1% of Cardio Diagnostics shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cardio Diagnostics beats China Pharma on 8 of the 14 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.97M	$3.39B	$6.33B	$12.47B
Dividend Yield	N/A	2.31%	2.80%	5.25%
P/E Ratio	-0.42	18.03	20.07	25.23
Price / Sales	309.48	297.14	565.46	82.53
Price / Cash	N/A	124.05	43.04	56.04
Price / Book	0.41	6.63	9.83	6.91
Net Income	-$6.50M	$24.40M	$3.56B	$334.11M
7 Day Performance	-15.30%	3.88%	0.26%	-0.02%
1 Month Performance	-20.92%	-2.84%	-1.29%	1.15%
1 Year Performance	-59.64%	62.79%	33.63%	30.68%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	1.3087 of 5 stars	$1.55 -7.7%	N/A	-61.3%	$4.97M	$14.83K	N/A	1	Positive News Earnings Report
AKAN Akanda	0.8081 of 5 stars	$30.00 -27.0%	N/A	-75.1%	$21.95M	$840K	N/A	110	Short Interest Increase Gap Down
VYNE VYNE Therapeutics	1.168 of 5 stars	$0.67 +1.5%	N/A	-46.4%	$21.86M	$570K	N/A	30	News Coverage Positive News Earnings Report High Trading Volume
KZIA Novogen	2.0232 of 5 stars	$13.45 +4.8%	$21.00 +56.1%	+287.1%	$21.23M	$30K	N/A	12	Short Interest Increase Gap Down
KTTA Pasithea Therapeutics	2.6678 of 5 stars	$0.85 +0.4%	$3.00 +252.9%	-9.4%	$21.11M	N/A	N/A	3	Earnings Report Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. AKAN, VYNE, KZIA, KTTA, and CPHI

How does Cardio Diagnostics compare to Akanda?

Summary

How does Cardio Diagnostics compare to VYNE Therapeutics?

Summary

How does Cardio Diagnostics compare to Novogen?

Summary

How does Cardio Diagnostics compare to Pasithea Therapeutics?

Summary

How does Cardio Diagnostics compare to China Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. AKAN, VYNE, KZIA, KTTA, and CPHI

How does Cardio Diagnostics compare to Akanda?

Which has preferable earnings and valuation, CDIO or AKAN?

Does the media favor CDIO or AKAN?

Do analysts rate CDIO or AKAN?

Is CDIO or AKAN more profitable?

Do insiders & institutionals have more ownership in CDIO or AKAN?

Which has more volatility and risk, CDIO or AKAN?

Summary

How does Cardio Diagnostics compare to VYNE Therapeutics?

Do analysts rate CDIO or VYNE?

Is CDIO or VYNE more profitable?

Which has preferable earnings and valuation, CDIO or VYNE?

Does the media favor CDIO or VYNE?

Which has more volatility and risk, CDIO or VYNE?

Do insiders & institutionals have more ownership in CDIO or VYNE?

Summary

How does Cardio Diagnostics compare to Novogen?

Do analysts prefer KZIA or CDIO?

Is KZIA or CDIO more profitable?

Which has higher earnings and valuation, KZIA or CDIO?

Does the media refer more to KZIA or CDIO?

Which has more risk & volatility, KZIA or CDIO?

Do institutionals & insiders hold more shares of KZIA or CDIO?

Summary

How does Cardio Diagnostics compare to Pasithea Therapeutics?

Does the media prefer KTTA or CDIO?

Do insiders and institutionals hold more shares of KTTA or CDIO?

Is KTTA or CDIO more profitable?

Do analysts prefer KTTA or CDIO?

Which has stronger valuation & earnings, KTTA or CDIO?

Which has more volatility and risk, KTTA or CDIO?

Summary

How does Cardio Diagnostics compare to China Pharma?

Which has better earnings & valuation, CDIO or CPHI?

Is CDIO or CPHI more profitable?

Does the media refer more to CDIO or CPHI?

Do analysts recommend CDIO or CPHI?

Which has more risk and volatility, CDIO or CPHI?

Do insiders & institutionals hold more shares of CDIO or CPHI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools